Al Hofuf

Researchers are investigating how a high-protein, high-fiber meal eaten before fasting affects feelings of fullness and blood sugar levels during fasting hours in healthy adults. This randomized crossover study compares a standardized high-protein, high-fiber pre-fast meal to a low-protein, low-fiber meal guided by dietary instructions, aiming to understand their impact on appetite and glycemic responses. Participants will complete two study periods, each lasting two consecutive days, with a three-day break in between. In one period, they will consume a provided high-protein, high-fiber meal including oats, Greek yogurt, peanut butter, dried cranberries, and almonds. In the other period, they will follow written instructions to consume a low-protein, low-fiber pre-fast meal without calorie limits. Throughout the study, participants feelings of hunger, fullness, desire to eat, and anticipated food intake will be measured at specific times during fasting. Blood sugar levels will be continuously monitored using a glucose monitor. Researchers will analyze the relationship between glucose changes and appetite sensations. The study includes fasting, meal consumption, monitoring, and washout phases to thoroughly evaluate effects.

Researchers are tracking patients with Fabry disease through an ongoing international observational program called the Fabry Registry. This registry collects routine clinical outcomes for patients regardless of whether they are receiving treatment. The study aims to better understand the diseases variability, progression, and natural history, including in women who carry one copy of the gene, and to help improve patient care by developing monitoring recommendations and reporting outcomes. Additionally, the registry evaluates the long-term safety and effectiveness of Fabrazyme4, a treatment used in Fabry disease. The registry includes a special pregnancy sub-registry for women with Fabry disease who are pregnant or have been pregnant. This sub-registry observes pregnancy outcomes and infant growth up to 36 months after birth, collecting medical and obstetric history and treatment details. No experimental treatments are given participants continue to receive their usual care as determined by their physicians. Data from both registries support regulatory requirements and ongoing research. Participants undergo regular clinical assessments and receive standard care from their doctors throughout the study. The research team collects data on disease progression, treatment effectiveness, pregnancy outcomes, and infant development. The study is observational, meaning no study drugs or procedures are administered. The total participation can last up to 33 years, allowing for long-term monitoring of safety and outcomes related to Fabry disease and pregnancy.

Researchers are tracking the natural history and clinical outcomes of patients with Gaucher disease through the ICGG Gaucher Registry, an international, multi-center observational program. This registry does not involve any experimental treatments, but collects information to better understand the variability, progression, and identification of Gaucher disease, aiming to improve patient care and therapeutic guidance. It also evaluates the long-term use of treatments like imiglucerase and eliglustat. The study includes two groups patients with Gaucher disease who receive routine clinical assessments and standard care as determined by their physicians, and a Pregnancy Sub-registry for women with Gaucher disease who are pregnant or have been pregnant. The Pregnancy Sub-registry collects information on pregnancy outcomes, complications, and infant growth up to 36 months postpartum, regardless of whether the women receive disease-specific therapy. Participants undergo clinical assessments and receive care according to their treating physicians decisions. Data collected includes medical history, pregnancy and birth details for the sub-registry, and patient outcomes over time. The primary goals are to provide recommendations for monitoring Gaucher disease patients, report outcomes to optimize care, and track pregnancy and infant growth outcomes. This ongoing registry allows long-term follow-up without experimental interventions.